D-Cycloserine as an Augmentation to Exposure Therapy for Specific Phobia
An NMDA partial agonist with a real mechanistic case for enhancing fear extinction has produced genuinely mixed results across trials. A patient whose exposure-therapy gains aren't holding between sessions tests whether the mechanism is worth trying anyway.
Marcus T., a 35-year-old man, has severe emetophobia (fear of vomiting) that has narrowed his diet, his travel, and his willingness to be around anyone visibly ill, present since his teenage years and never previously treated. He has started a structured exposure-therapy program with a therapist experienced in this specific phobia subtype, and initial sessions have gone reasonably well, though his therapist notes his between-session anxiety carries over less consistently than she'd like, meaning gains made in one session don't always hold by the next.
D-cycloserine, an NMDA receptor partial agonist originally developed as an antibiotic, has real mechanistic plausibility here: NMDA receptor activity is required for the synaptic plasticity underlying fear extinction, and a single dose taken shortly before an exposure session is thought to enhance whatever extinction learning occurs that day. But the replication picture across trials is genuinely mixed — some studies show real augmentation benefit, particularly early in a course of therapy, while others show no meaningful difference from placebo, and there's some suggestion the drug may actually need to be paired with a genuinely successful session to help, doing little or nothing on a day exposure goes poorly.
He's candid that he found the D-cycloserine idea himself through a patient forum for emetophobia, and arrives already hopeful in a way that concerns his therapist slightly — not because the drug isn't worth trying, but because a strong expectation of a quick fix, if unmet, risks discouraging him from the harder, slower work exposure therapy actually requires regardless of any medication.
An evidence-mixed augmentation strategy
The mechanism is real and specific — D-cycloserine's NMDA partial agonism directly supports the synaptic plasticity extinction learning depends on, and his specific problem, gains not carrying over reliably between sessions, is exactly the pattern some trials show the drug helping with when dosed shortly before a session.
I'd want to be honest with him that the replication evidence is genuinely mixed, not just early-stage — several well-powered trials found no benefit over placebo, and there's real reason to think it may only help when the session itself goes well, which we can't guarantee in advance. This isn't a drug I'd want him relying on as if it's a proven augmentation strategy.
Both things can be true: it's a legitimate, low-risk option to offer given the real mechanism and his specific carryover problem, and he needs to hear the mixed-evidence picture plainly before deciding, including that a single missed or poor-quality exposure session that day would likely mean the dose did little. Offered as an informed trial, not a confident recommendation.
Agreed: he'll trial D-cycloserine before his next several sessions, with the therapist tracking whether carryover between sessions improves — discontinuing without hesitation if no clear difference emerges after a defined number of doses.